Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Next Previous
Search
Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Coronary disorders; Hypercholesterolaemia; Myocardial infarction; Peripheral arterial disorders; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms PROFICIO; VESALIUS-CV
  • Sponsors Amgen

    • Most Recent Events

    • 07 Feb 2025 Planned End Date changed from 26 May 2025 to 2 Sep 2025.
    • 07 Feb 2025 Planned primary completion date changed from 26 May 2025 to 2 Sep 2025.
    • 04 Feb 2025 According to an Amgen media release, data readout is event driven and anticipated in H2 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top